House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Dermatology

Atopic Dermatitis

IAP · 2026 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The IAP chapter presents a stepwise approach to childhood atopic dermatitis, centred on skin-barrier care, appropriate topical anti-inflammatory treatment and family education. Assessment includes severity, infection, sleep and quality of life; difficult or atypical disease requires specialist review.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Assess the disease and consider alternatives

  • Take a history of onset, chronicity, family atopy, triggers and previous treatment. Examine morphology and age-related distribution: facial and extensor disease in infants, and more flexural disease in older children. [1]
  • Assess severity using SCORAD, EASI or POEM. Look for secondary infection, complications and associated asthma, allergic rhinitis or conjunctivitis, and ask about sleep disturbance and psychosocial impact. [1]
  • Consider mimics or coexisting disease, including seborrhoeic or contact dermatitis, psoriasis, scabies, immunodeficiency and nutritional or metabolic dermatoses. Early severe exudative disease with recurrent infection should raise concern for immunodeficiency. [1]

Make consistent skin care the foundation

  • Use a short daily bath of 5–10 minutes in warm water at 27–30°C. Choose a mild, non-soap, fragrance-free, pH-balanced cleanser to reduce disruption of the skin barrier. [1]
  • Apply preservative-free, fragrance-free moisturizers liberally and regularly, generally 3–4 times daily and preferably along hair growth. Continue emollients during remission. Wet wraps may be considered for severe dryness or acute flares. [1]
  • Prefer smooth, light cotton clothing and reduce exposure to irritants, smoke and pollution. Reduce aeroallergen exposure in sensitized children; restrict foods only when an allergen is proven, avoiding unnecessary elimination diets. [1]

Treat flares and prevent relapse with appropriate potency

  • During a flare, apply topical corticosteroid twice daily to affected areas until lesions resolve. Review after 2 weeks and, once controlled, step down to a lower potency suited to the child’s age and the site. [1]
  • For proactive maintenance, apply topical corticosteroid twice weekly to previously affected areas for up to 16 weeks as needed. Use hydrated skin, liberal emollients and the lowest effective age-appropriate potency. [1]
  • Teach the fingertip-unit method for topical dosing. The chapter defines it using an adult index finger and a 5-mm nozzle, with one unit covering roughly two adult flat-hand areas. [1]
  • Avoid continuous high-potency corticosteroid use or use on sensitive areas. Discuss potential skin atrophy and other local adverse effects, and the risk of systemic effects with prolonged large quantities of potent corticosteroid. [1]
  • Pimecrolimus 1% and tacrolimus 0.03% or 0.1% are described as options for flares and maintenance. Burning, stinging or redness may occur; the chapter does not supply a complete age-by-strength prescribing rule. [1]

Treat infection and escalate refractory disease

  • Use antibiotics for secondary infection. Bleach baths containing 0.005% sodium hypochlorite may help prevent colonization. Do not use prolonged topical antibiotics on eczema lesions or recommend irritant antiseptics for routine skin care. [1]
  • Do not routinely prescribe systemic corticosteroids. The chapter describes a short course only for acute severe flares and lists cyclosporine, azathioprine, methotrexate and mycophenolate for refractory disease; escalation is a reason for specialist referral. [1]
  • The chapter recommends dupilumab for moderate-to-severe disease in patients older than 6 months and states Indian licensing for those older than 12 years. These distinct thresholds must not be merged into a single statement of Indian approval. [1]
  • Consider phototherapy for chronic moderate-to-severe disease after inadequate response to optimized topicals, or when systemic treatment is contraindicated, impractical or inappropriate. Narrowband UVB is preferred; frequent visits make treatment less suitable for very young children. [1]

Refer appropriately and support the family

  • Refer severe, atypical, persistent or treatment-refractory disease, suspected immunodeficiency or another underlying disorder, major quality-of-life impairment or psychological distress, and cases needing systemic treatment, biologics or phototherapy. [1]
  • Teach families that eczema is chronic and relapsing. Demonstrate bathing, moisturization and correct topical treatment, identify triggers, address treatment fears, and support the child and family emotionally. [1]

Limitations and use

  • Graphical diagnostic criteria, red-flag diagrams and management algorithms are not reconstructed from unavailable figure content. The document does not give complete age-specific licensing or monitoring requirements for every systemic or topical drug. Dupilumab age and Indian licensing statements below reflect this chapter, not a separate current regulatory verification.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Atopic Dermatitis

    Selected recommendation material consulted

Practice guideline

Publication details

Issuing organisation
IAP
Resource type
Practice guideline · House clinical summary
Source setting
India

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Assess the disease and consider alternatives
  • Make consistent skin care the foundation
  • Treat flares and prevent relapse with appropriate potency
  • Treat infection and escalate refractory disease
  • Refer appropriately and support the family
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House